Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Editas Medicine Inc (NASDAQ: EDIT) closed at $3.21 down -5.03% from its previous closing price of $3.38. In other words, the price has decreased by -$5.03 from its previous closing price. On the day, 1.52 million shares were traded. EDIT stock price reached its highest trading level at $3.42 during the session, while it also had its lowest trading level at $3.18.
Ratios:
For a deeper understanding of Editas Medicine Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.85 and its Current Ratio is at 3.85. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2024, Upgraded its rating to Buy and sets its target price to $15 from $13 previously.
On May 09, 2024, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight but kept the price unchanged to $7.
Citigroup Upgraded its Neutral to Buy on October 24, 2023, while the target price for the stock was maintained at $11.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 04 ’24 when Mei Baisong sold 518 shares for $3.42 per share. The transaction valued at 1,774 led to the insider holds 133,895 shares of the business.
O’Neill Gilmore Neil sold 1,555 shares of EDIT for $5,325 on Sep 04 ’24. The CEO now owns 313,724 shares after completing the transaction at $3.42 per share. On Sep 03 ’24, another insider, O’Neill Gilmore Neil, who serves as the Officer of the company, bought 3,000 shares for $3.92 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 278770208 and an Enterprise Value of 24335360. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.95 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 0.363 whereas that against EBITDA is -0.117.
Stock Price History:
Over the past 52 weeks, EDIT has reached a high of $11.69, while it has fallen to a 52-week low of $3.15. The 50-Day Moving Average of the stock is -19.00%, while the 200-Day Moving Average is calculated to be -48.13%.
Shares Statistics:
For the past three months, EDIT has traded an average of 1.78M shares per day and 1991090 over the past ten days. A total of 81.77M shares are outstanding, with a floating share count of 81.70M. Insiders hold about 0.94% of the company’s shares, while institutions hold 69.58% stake in the company. Shares short for EDIT as of 1726185600 were 18964676 with a Short Ratio of 10.63, compared to 1723680000 on 16896231. Therefore, it implies a Short% of Shares Outstanding of 18964676 and a Short% of Float of 29.13.
